Pancreatic cancer is one of the most challenging malignancies to diagnose early, as it presents few or no symptoms in its initial stages. It is also known to have the lowest survival rate among all cancers. Additionally, the tumor microenvironment (TME) of pancreatic cancer poses significant barriers to drug penetration, driving the development of innovative therapeutic strategies to overcome these challenges.
To better replicate the pancreatic cancer microenvironment, we conducted a collaborative study with Lambda Biologics to establish a tumor organoid model and develop a co-culture platform incorporating cancer-associated fibroblasts (CAF).
By leveraging this platform, we aim to accurately assess drug penetration within tumor tissues and facilitate the development of highly effective therapeutic candidates.